The development of a rapid assay for prenatal testing of common aneuploidies and microdeletion syndromes

Objective To develop a novel, rapid prenatal assay for pregnancies with high likelihood of normal karyotypes, using BACs‐on‐Beads™ technology, a suspension array‐based multiplex assay that employs Luminex® xMAP® technology, for the detection of gains and losses in chromosomal DNA. Methods Fifteen re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Prenatal diagnosis 2011-08, Vol.31 (8), p.778-787
Hauptverfasser: Shaffer, Lisa G., Coppinger, Justine, Morton, S. Annie, Alliman, Sarah, Burleson, Jessica, Traylor, Ryan, Walker, Cathryn, Byerly, Steve, Lamb, Allen N., Schultz, Roger, Ravnan, J. Britt, Kashork, Catherine D., Torchia, Beth S., Sulpizio, Scott, Sundin, Kyle, Schermer, Mack, Adler, Karl, Dallaire, Stephanie, Ballif, Blake C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To develop a novel, rapid prenatal assay for pregnancies with high likelihood of normal karyotypes, using BACs‐on‐Beads™ technology, a suspension array‐based multiplex assay that employs Luminex® xMAP® technology, for the detection of gains and losses in chromosomal DNA. Methods Fifteen relatively common microdeletions were selected that are not detectable, or may be missed, by karyotyping and usually do not present with abnormal ultrasound findings. Chromosomes 13, 18, 21, X, and Y were included. We validated the assay with 430 samples. Results All microdeletions and aneuploidies were correctly identified, except for a 69,XXX incorrectly identified as a normal female and a male with ∼20% maternal cell contamination (MCC) that could not be distinguished from 69,XXY. MCC became apparent at 20 to 30%. Mosaicism was identified at 30 to 35% abnormal cells. Conclusion We have developed an alternative to fluorescence in situ hybridization (FISH) aneuploidy screening and microarray analysis in otherwise normal pregnancies undergoing invasive testing. We demonstrated that the assay will detect all microdeletions and aneuploidies of regions covered on the assay. We developed analytical software that displays results for well‐characterized syndromes but not abnormalities of unclear clinical significance. This assay is likely to be preferred by women seeking testing beyond routine karyotyping but who desire more information than provided by aneuploidy FISH. Copyright © 2011 John Wiley & Sons, Ltd.
ISSN:0197-3851
1097-0223
1097-0223
DOI:10.1002/pd.2766